{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2024-04-03T16:00:00.000Z","role":"Approver"},{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10135","date":"2024-04-03T17:10:36.440Z","role":"Publisher"}],"curationReasons":{"id":"cg:NewCuration"},"earliestArticle":{"id":"https://pubmed.ncbi.nlm.nih.gov/25678555","type":"dc:BibliographicResource","dc:abstract":"In mitochondria, carbamoyl-phosphate synthetase 1 activity produces carbamoyl phosphate for urea synthesis, and deficiency results in hyperammonemia. Cytoplasmic carbamoyl-phosphate synthetase 2, however, is part of a tri-functional enzyme encoded by CAD; no human disease has been attributed to this gene. The tri-functional enzyme contains carbamoyl-phosphate synthetase 2 (CPS2), aspartate transcarbamylase (ATCase) and dihydroorotase (DHOase) activities, which comprise the first three of six reactions required for de novo pyrimidine biosynthesis. Here we characterize an individual who is compound heterozygous for mutations in different domains of CAD. One mutation, c.1843-1G>A, results in an in-frame deletion of exon 13. The other, c.6071G>A, causes a missense mutation (p.Arg2024Gln) in a highly conserved residue that is essential for carbamoyl-phosphate binding. Metabolic flux studies showed impaired aspartate incorporation into RNA and DNA through the de novo synthesis pathway. In addition, CTP, UTP and nearly all UDP-activated sugars that serve as donors for glycosylation were decreased. Uridine supplementation rescued these abnormalities, suggesting a potential therapy for this new glycosylation disorder.","dc:creator":"Ng BG","dc:date":"2015","dc:title":"Biallelic mutations in CAD, impair de novo pyrimidine biosynthesis and decrease glycosylation precursors."},"evidence":[{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:4ad93d85-855a-4289-9c6d-e5f60721efe2","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:7930b23d-1a58-492d-b363-00df5f23c902","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionB"},"dc:description":"The CAD gene encodes a trifunctional protein which is associated with the enzymatic activity of the first 3 enzymes in the 6-step pathway of de novo pyrimidine biosynthesis. Rare genetic disorders occur in the last 3 steps of the de novo pathway (e.g. Miller syndrome which is caused by mutations in DHODH). One important product of the de novo pyrimidine biosynthesis, UTP, is used to form UDP-GlcNAc, UDP-GalNAc, UDP-Glc, and UDP-Gal. These sugars, which serve as donors for glycosylation, were all reduced in patient cells. Uridine supplementation rescued these abnormalities, suggesting a therapy for this disorder (similar to Miller syndrome).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25678555","rdfs:label":"Pyrimidine biosynthesis"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":1,"dc:description":"Increasing points based on PMID: 28007989 where 2 patients were given uridine supplementation which led to cessation of seizures and improvement in developmental progress. This further supports the role of this gene in the pathway."}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:489271ea-ed13-4372-8069-8597877de137","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:dd6d2eb6-ff36-413f-8b5d-2d90cbf36480","type":"FunctionalAlteration","dc:description":"CAD-KO cells are unable to grow in the absence of uridine. In order to confirm that CAD is needed for de novo pyrimidine synthesis and cell growth in the absence of uridine, the authors measure proliferation of CAD-KO cells transfected with GFP-CAD with variants found in patients. Overall, 16 of the 34 variants tested have a deleterious effet on CAD activity.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/32461667","type":"dc:BibliographicResource","dc:abstract":"Pathogenic autosomal recessive variants in CAD, encoding the multienzymatic protein initiating pyrimidine de novo biosynthesis, cause a severe inborn metabolic disorder treatable with a dietary supplement of uridine. This condition is difficult to diagnose given the large size of CAD with over 1000 missense variants and the nonspecific clinical presentation. We aimed to develop a reliable and discerning assay to assess the pathogenicity of CAD variants and to select affected individuals that might benefit from uridine therapy.","dc:creator":"Del CaÃ±o-Ochoa F","dc:date":"2020","dc:title":"Cell-based analysis of CAD variants identifies individuals likely to benefit from uridine therapy."},"rdfs:label":"CRISPR/Cas9 CAD KO"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":1,"dc:description":"Uridine supplementation is a known treatment for individuals with this condition. Follow up study in PMID: 37540500 showed that p.G58S, p.R238C, p.R1475Q, p.K1482M, p.S1538L, p.W1581R, p.R1617Q, p.H1687R, p.R1722W, and p.R1785H did not rescue the growth in media without uridine."}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1},{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:62d356a5-6e9a-4fa2-b6cf-e44c2132917b","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1075a8c1-e7cb-41ea-81ad-f897e8b9ce7d","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"The results suggest that the rudimentary mutation interferes with the biosynthesis of pyrimidines, thus causing a fundamental  metabolic disturbance responsible for  the  rudimentary syndrome. Homozygous females are sterile but the fertility of rudimentary females  is strongly  enhanced when they are cultured on RNA- or cytidine-enriched yeast-sucrose medium. ","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/5004701","type":"dc:BibliographicResource","dc:creator":"Norby S","dc:date":"1970","dc:title":"A specific nutritional requirement for pyrimidines in rudimentary mutants of Drosophila melanogaster."},"rdfs:label":"Norby 1970 Drosophila"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5,"dc:description":"Model organism shows that the gene is involved in pyrimidine biosynthesis, similar to humans, but overall phenotype is not easily related to the human phenotype."},{"id":"cggv:a09d2066-5043-44b9-9e47-2d1568758703","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:5b45bad4-b8bb-4bf1-a20b-bedbed83029d","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Injection of orotic acid or uridine in 24 hpf mutants was able to rescue the retinal defects of the \"perplexed\" mutant indicated by eye size and plexiform layer formation (Figure 4), further showing that CAD is part of the uridine pathway. The authors compared the phenotype to zebrafish that lack the UDP-glucuronic acid/UDP-N-acetylgalactosamine dual transporter and zebrafish that have a mutation in the UDP-glucuronic acid decarboxylase gene and found a similar disruption in the jaw (but eyes were normal).","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/15937129","type":"dc:BibliographicResource","dc:abstract":"The zebrafish perplexed mutation disrupts cell proliferation and differentiation during retinal development. In addition, growth and morphogenesis of the tectum, jaw, and pectoral fins are also affected. Positional cloning was used to identify a mutation in the carbamoyl-phosphate synthetase2-aspartate transcarbamylase-dihydroorotase (cad) gene as possibly causative of the perplexed mutation and this was confirmed by gene knockdown and pyrimidine rescue experiments. CAD is required for de novo biosynthesis of pyrimidines that are required for DNA, RNA, and UDP-dependent protein glycosylation. Developmental studies of several vertebrate species showed high levels of cad expression in tissues where mutant phenotypes were observed. Confocal time-lapse analysis of perplexed retinal cells in vivo showed a near doubling of the cell cycle period length. We also compared the perplexed mutation with mutations that affect either DNA synthesis or UDP-dependent protein glycosylation. Cumulatively, our results suggest an essential role for CAD in facilitating proliferation and differentiation events in a tissue-specific manner during vertebrate development. Both de novo DNA synthesis and UDP-dependent protein glycosylation are important for the perplexed phenotypes.","dc:creator":"Willer GB","dc:date":"2005","dc:title":"Analysis of the Zebrafish perplexed mutation reveals tissue-specific roles for de novo pyrimidine synthesis during development."},"rdfs:label":"Willer 2005 Zebrafish"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5,"dc:description":"The authors compared the phenotype of CAD mutants to those with disrupted UDP-dependent glycosylation and found that some of the phenotypes were similar, but did not provide a direct correlation. Giving 0.5 pt since uridine partially rescued the phenotype."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3},{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:0aff78f5-d807-42eb-86cf-ec07749a255d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0aff78f5-d807-42eb-86cf-ec07749a255d","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":6,"allele":{"id":"cggv:6ff7c51c-2e54-4500-bf5b-b8d7c567ce81","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.5366G>A (p.Arg1789Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA346222693"}},"detectionMethod":"Two panels- 1 with 34 genes for CDA and erythrocyte membrane defects and another with 71 genes for CDA, RBC membrane defects, DBD, hemolytic anemia.","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0001972","obo:HP_0031965","obo:HP_0001250"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:00fecbcf-5619-46b7-8875-a7ba97b4aa61_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:6ff7c51c-2e54-4500-bf5b-b8d7c567ce81"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/29396846","type":"dc:BibliographicResource","dc:abstract":"Mutations in more than 70 genes cause hereditary anemias (HA), a highly heterogeneous group of rare/low frequency disorders in which we included: hyporegenerative anemias, as congenital dyserythropoietic anemia (CDA) and Diamond-Blackfan anemia; hemolytic anemias due to erythrocyte membrane defects, as hereditary spherocytosis and stomatocytosis; hemolytic anemias due to enzymatic defects. The study describes the diagnostic workflow for HA, based on the development of two consecutive versions of a targeted-NGS panel, including 34 and 71 genes, respectively. Seventy-four probands from 62 unrelated families were investigated. Our study includes the most comprehensive gene set for these anemias and the largest cohort of patients described so far. We obtained an overall diagnostic yield of 64.9%. Despite 54.2% of cases showed conclusive diagnosis fitting well to the clinical suspicion, the multi-gene analysis modified the original clinical diagnosis in 45.8% of patients (nonmatched phenotype-genotype). Of note, 81.8% of nonmatched patients were clinically suspected to suffer from CDA. Particularly, 45.5% of the probands originally classified as CDA exhibited a conclusive diagnosis of chronic anemia due to enzymatic defects, mainly due to mutations in PKLR gene. Interestingly, we also identified a syndromic CDA patient with mild anemia and epilepsy, showing a homozygous mutation in CAD gene, recently associated to early infantile epileptic encephalopathy-50 and CDA-like anemia. Finally, we described a patient showing marked iron overload due to the coinheritance of PIEZO1 and SEC23B mutations, demonstrating that the multi-gene approach is valuable not only for achieving a correct and definitive diagnosis, but also for guiding treatment.","dc:creator":"Russo R","dc:date":"2018","dc:title":"Multi-gene panel testing improves diagnosis and management of patients with hereditary anemias."}},"rdfs:label":"RP1_112"},{"id":"cggv:00fecbcf-5619-46b7-8875-a7ba97b4aa61","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:00fecbcf-5619-46b7-8875-a7ba97b4aa61_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:0dbbdf3e-b3db-41a3-9763-db63d8056b8b_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:0dbbdf3e-b3db-41a3-9763-db63d8056b8b","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":43,"allele":[{"id":"cggv:a27bfc3b-9f6b-4f97-8f3f-66ab60c5d9f9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.5860G>A (p.Glu1954Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA346223779"}},{"id":"cggv:81a7d6f5-928b-4650-8e8d-310898c3570a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.3194G>A (p.Trp1065Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA346213891"}}],"detectionMethod":"Patients were diagnosed via proband-only, proband-parent trio exome, or multigene panel but the authors do not specify for each patient. All parents were confirmed carriers.","phenotypes":["obo:HP_0001903","obo:HP_0001251","obo:HP_0001263","obo:HP_0004823","obo:HP_0001250"],"previousTesting":false,"sex":"Female","variant":[{"id":"cggv:b2eee55a-baef-46fe-a4df-b0f75493fe01_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:81a7d6f5-928b-4650-8e8d-310898c3570a"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/32820246","type":"dc:BibliographicResource","dc:abstract":"Biallelic CAD variants underlie CAD deficiency (or early infantile epileptic encephalopathy-50, [EIEE-50]), an error of pyrimidine de novo biosynthesis amenable to treatment via the uridine salvage pathway. We further define the genotype and phenotype with a focus on treatment.","dc:creator":"Rymen D","dc:date":"2020","dc:title":"Expanding the clinical and genetic spectrum of CAD deficiency: an epileptic encephalopathy treatable with uridine supplementation."}},{"id":"cggv:cee44d45-c940-4fd6-81d8-4698a58a3f3c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:a27bfc3b-9f6b-4f97-8f3f-66ab60c5d9f9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820246"}],"rdfs:label":"UP6.1"},{"id":"cggv:cee44d45-c940-4fd6-81d8-4698a58a3f3c","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:cee44d45-c940-4fd6-81d8-4698a58a3f3c_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:b2eee55a-baef-46fe-a4df-b0f75493fe01","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:b2eee55a-baef-46fe-a4df-b0f75493fe01_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:331b20de-7c2f-40eb-bcd8-eb965d2d8ff9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:331b20de-7c2f-40eb-bcd8-eb965d2d8ff9","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"allele":[{"id":"cggv:2e7cb1ed-331d-4448-92f9-a0143d3b3a6b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.111del (p.Glu38ArgfsTer13)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2586968857"}},{"id":"cggv:41a2d849-6b5c-4e29-a29f-ac11fcd13b27","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.3775G>A (p.Val1259Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA346216614"}}],"detectionMethod":"Trio WES","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001903","obo:HP_0004823","obo:HP_0001272","obo:HP_0000486","obo:HP_0001250","obo:HP_0002376","obo:HP_0007663","obo:HP_0002059"],"previousTesting":true,"previousTestingDescription":"Blood biochemical tests and metabolic profiles were unrevealing.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"cggv:2480429b-67ad-4083-ab43-758a8c831286_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:2e7cb1ed-331d-4448-92f9-a0143d3b3a6b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/32117025","type":"dc:BibliographicResource","dc:abstract":"CAD encodes a multifunctional enzyme involved in ","dc:creator":"Zhou L","dc:date":"2020","dc:title":"A Patient With CAD Deficiency Responsive to Uridine and Literature Review."}},{"id":"cggv:42d8dd6a-2f35-4905-9d25-086d560a9d1c_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:41a2d849-6b5c-4e29-a29f-ac11fcd13b27"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32117025"}],"rdfs:label":"Zhou 2020 Proband"},{"id":"cggv:42d8dd6a-2f35-4905-9d25-086d560a9d1c","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:42d8dd6a-2f35-4905-9d25-086d560a9d1c_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:2480429b-67ad-4083-ab43-758a8c831286","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:2480429b-67ad-4083-ab43-758a8c831286_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:71616fad-48f3-4771-af60-6d18a217f538_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:71616fad-48f3-4771-af60-6d18a217f538","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":9,"allele":[{"id":"cggv:9d812a5f-eefa-4be2-89a1-a71e65e340c9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.2617_2620del (p.Asp873AsnfsTer8)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA645293935"}},{"id":"cggv:bd843ce5-5153-4cc0-b806-1ae585e83779","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.5429G>A (p.Arg1810Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1573863"}}],"detectionMethod":"Patients were diagnosed via proband-only, proband-parent trio exome, or multigene panel but the authors do not specify for each patient. All parents were confirmed carriers.","ethnicity":{"id":"cg:NotHispanicOrLatino"},"phenotypes":["obo:HP_0001272","obo:HP_0001250","obo:HP_0007018","obo:HP_0002353","obo:HP_0000639","obo:HP_0001903","obo:HP_0003390","obo:HP_0001263"],"previousTesting":false,"sex":"Female","variant":[{"id":"cggv:93210f4b-79ce-4621-9ca2-57771a715445_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:9d812a5f-eefa-4be2-89a1-a71e65e340c9"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820246"},{"id":"cggv:58efefae-e497-4442-a8ff-e3876b41e50a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:bd843ce5-5153-4cc0-b806-1ae585e83779"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820246"}],"rdfs:label":"UP2"},{"id":"cggv:58efefae-e497-4442-a8ff-e3876b41e50a","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:58efefae-e497-4442-a8ff-e3876b41e50a_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:93210f4b-79ce-4621-9ca2-57771a715445","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:93210f4b-79ce-4621-9ca2-57771a715445_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:bffdb1d4-c128-4b80-96ac-d83faeb24000_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:bffdb1d4-c128-4b80-96ac-d83faeb24000","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"allele":[{"id":"cggv:1b8435ae-e942-48d7-b7ac-371fe7fd2fc2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.6071G>A (p.Arg2024Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1574096"}},{"id":"cggv:6c2c4940-9301-4c2e-949e-be8692f7ef3b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.1843-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA251247"}}],"detectionMethod":"Parents and unaffected sibling were tested.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0010862","obo:HP_0002136","obo:HP_0001250","obo:HP_0004823","obo:HP_0000750","obo:HP_0001252","obo:HP_0001508","obo:HP_0002014","obo:HP_0001947"],"previousTesting":true,"previousTestingDescription":"Fanconi and Shwachman-Diamond Syndromes excluded. No variants in SEC23B. Urine amino and organic acids, plasma amino acids, uric acid, fasting lipid profile, lactate, pyruvate, acylcarnitine, free and total carnitine, immunoglobulins, vitamin D, vitamin E, CSF all normal. Vitamin A decreased. Ammonia levels increased. Urine purines and pyrimidines, orotic acid normal.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"cggv:bb019854-efe0-4c3e-a1fe-4577a7bc1df8_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:1b8435ae-e942-48d7-b7ac-371fe7fd2fc2"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25678555"},{"id":"cggv:a0cf8355-a352-4b9b-9374-dce7207bb9df_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:6c2c4940-9301-4c2e-949e-be8692f7ef3b"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25678555"}],"rdfs:label":"UDP4003"},{"id":"cggv:a0cf8355-a352-4b9b-9374-dce7207bb9df","type":"obo:SEPIO_0004097","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:a0cf8355-a352-4b9b-9374-dce7207bb9df_variant_evidence_item"},{"id":"cggv:a0cf8355-a352-4b9b-9374-dce7207bb9df_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"cDNA analysis of patient fibroblasts showed an abnormally spliced fragment corresponding to an in-frame deletion of exon 13. "}],"strengthScore":1.5,"dc:description":"Reducing points since NMD is not expected. The deletion does include part of the CPS2 domain so only reducing by 0.5 pt."},{"id":"cggv:bb019854-efe0-4c3e-a1fe-4577a7bc1df8","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:bb019854-efe0-4c3e-a1fe-4577a7bc1df8_variant_evidence_item"},{"id":"cggv:bb019854-efe0-4c3e-a1fe-4577a7bc1df8_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"p.Arg2024Gln only partially rescued growth defect in complementation assay while wt fully rescued."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4_ar_el","type":"EvidenceLine","specifiedBy":"GeneValidityOverallAutosomalRecessiveVariantEvidenceCriteria","strengthScore":12},{"id":"cggv:8436dfe3-ee60-477d-9d1d-e5a422519150_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:8436dfe3-ee60-477d-9d1d-e5a422519150","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":4,"allele":{"id":"cggv:79917421-85e7-484d-a67d-e981f9bdbaed","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.98T>G (p.Met33Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1572325"}},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0002283","obo:HP_0001251","obo:HP_0001263","obo:HP_0001903","obo:HP_0004823","obo:HP_0002376","obo:HP_0001250"],"previousTesting":true,"previousTestingDescription":"White blood cell counts and platelets, blood gas analysis, serum transferrin isoelectric focussing, lactate and ammonia, plasma amino acids, urinary organic acids, purines and pyrimidines, and orotic acid were unremarkable.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:37988c78-eb9d-4ee9-9240-ce46fb955bbd_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:79917421-85e7-484d-a67d-e981f9bdbaed"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28007989","type":"dc:BibliographicResource","dc:abstract":"Unexplained global developmental delay and epilepsy in childhood pose a major socioeconomic burden. Progress in defining the molecular bases does not often translate into effective treatment. Notable exceptions include certain inborn errors of metabolism amenable to dietary intervention. CAD encodes a multifunctional enzyme involved in de novo pyrimidine biosynthesis. Alternatively, pyrimidines can be recycled from uridine. Exome sequencing in three families identified biallelic CAD mutations in four children with global developmental delay, epileptic encephalopathy, and anaemia with anisopoikilocytosis. Two died aged 4 and 5 years after a neurodegenerative disease course. Supplementation of the two surviving children with oral uridine led to immediate cessation of seizures in both. A 4-year-old female, previously in a minimally conscious state, began to communicate and walk with assistance after 9 weeks of treatment. A 3-year-old female likewise showed developmental progress. Blood smears normalized and anaemia resolved. We establish CAD as a gene confidently implicated in this neurometabolic disorder, characterized by co-occurrence of global developmental delay, dyserythropoietic anaemia and seizures. While the natural disease course can be lethal in early childhood, our findings support the efficacy of uridine supplementation, rendering CAD deficiency a treatable neurometabolic disorder and therefore a potential condition for future (genetic) newborn screening.","dc:creator":"Koch J","dc:date":"2017","dc:title":"CAD mutations and uridine-responsive epileptic encephalopathy."}},"rdfs:label":"F1:II.2"},{"id":"cggv:37988c78-eb9d-4ee9-9240-ce46fb955bbd","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:37988c78-eb9d-4ee9-9240-ce46fb955bbd_variant_evidence_item"},{"id":"cggv:37988c78-eb9d-4ee9-9240-ce46fb955bbd_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Experimental studies have shown that this missense change affects CAD function (PMID: 32461667)"}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:206ddbf9-13ae-4bde-8d2a-ccdf76b69db9_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:206ddbf9-13ae-4bde-8d2a-ccdf76b69db9","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"allele":[{"id":"cggv:5b678887-55ae-4f6c-aa9d-54f111e20134","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.5365C>T (p.Arg1789Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1573827"}},{"id":"cggv:4aa6f192-f680-4d16-850a-da9189153620","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.1843-3C>T","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA16043926"}}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001272","obo:HP_0011471","obo:HP_0002015","obo:HP_0001263","obo:HP_0001903","obo:HP_0004823","obo:HP_0002376","obo:HP_0001250","obo:HP_0002059"],"previousTesting":true,"previousTestingDescription":"White blood cell counts and platelets, blood gas analysis, serum transferrin isoelectric focussing, lactate and ammonia, plasma amino acids, urinary organic acids, purines and pyrimidines, and orotic acid were unremarkable.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":[{"id":"cggv:2f784b40-539b-4162-825b-cf90bedd378f_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:4aa6f192-f680-4d16-850a-da9189153620"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28007989"},{"id":"cggv:b5ef2a13-e070-4024-bb37-887d71edefa3_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:5b678887-55ae-4f6c-aa9d-54f111e20134"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28007989"}],"rdfs:label":"F2:II.2"},{"id":"cggv:2f784b40-539b-4162-825b-cf90bedd378f","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:2f784b40-539b-4162-825b-cf90bedd378f_variant_evidence_item"}],"strengthScore":0.1},{"id":"cggv:b5ef2a13-e070-4024-bb37-887d71edefa3","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:b5ef2a13-e070-4024-bb37-887d71edefa3_variant_evidence_item"}],"strengthScore":1.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:da859de6-bfc8-4ec6-8604-8cef93755645_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:da859de6-bfc8-4ec6-8604-8cef93755645","type":"Proband","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":5,"allele":{"id":"cggv:79917421-85e7-484d-a67d-e981f9bdbaed"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001272","obo:HP_0002376","obo:HP_0004823","obo:HP_0011471","obo:HP_0001263","obo:HP_0001250","obo:HP_0002059","obo:HP_0001251","obo:HP_0002015","obo:HP_0001903"],"previousTesting":true,"previousTestingDescription":"White blood cell counts and platelets, blood gas analysis, serum transferrin isoelectric focussing, lactate and ammonia, plasma amino acids, urinary organic acids, purines and pyrimidines, and orotic acid were unremarkable.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"cggv:0de35150-536a-435a-a4f5-5f1f3de92f0b_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:79917421-85e7-484d-a67d-e981f9bdbaed"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:Homozygous"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28007989"},"rdfs:label":"F3:II.4"},{"id":"cggv:0de35150-536a-435a-a4f5-5f1f3de92f0b","type":"obo:SEPIO_0004097","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:0de35150-536a-435a-a4f5-5f1f3de92f0b_variant_evidence_item"},{"id":"cggv:0de35150-536a-435a-a4f5-5f1f3de92f0b_function_evidence_item","type":"VariantFunctionalImpactEvidence","functionalDataSupport":"Yes","dc:description":"Experimental studies have shown that this missense change affects CAD function (PMID: 32461667)."}],"strengthScore":0.5}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"},{"id":"cggv:bd683bdb-3a6a-496c-ba6a-299961375404_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"cggv:bd683bdb-3a6a-496c-ba6a-299961375404","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":8,"allele":[{"id":"cggv:bd843ce5-5153-4cc0-b806-1ae585e83779"},{"id":"cggv:44c9d11a-bdce-4bbd-9d50-e49d3d03c261","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004341.5(CAD):c.223-2A>G","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA346197474"}}],"detectionMethod":"Patients were diagnosed via proband-only, proband-parent trio exome, or multigene panel but the authors do not specify for each patient. All parents were confirmed carriers.","phenotypes":["obo:HP_0001263","obo:HP_0001250","obo:HP_0002015","obo:HP_0001935"],"previousTesting":false,"sex":"Male","variant":[{"id":"cggv:e6298385-e40d-4d57-bab0-bb3311adbfd2_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:bd843ce5-5153-4cc0-b806-1ae585e83779"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820246"},{"id":"cggv:ed572a14-2587-495d-8bc8-12c6023f047a_variant_evidence_item","type":"obo:SEPIO_0004116","allele":{"id":"cggv:44c9d11a-bdce-4bbd-9d50-e49d3d03c261"},"alleleOrigin":{"id":"obo:GENO_0000888"},"zygosity":{"id":"cg:TwoVariantsInTrans"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/32820246"}],"rdfs:label":"UP9"},{"id":"cggv:ed572a14-2587-495d-8bc8-12c6023f047a","type":"obo:SEPIO_0004097","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:ed572a14-2587-495d-8bc8-12c6023f047a_variant_evidence_item"}],"strengthScore":1.5},{"id":"cggv:e6298385-e40d-4d57-bab0-bb3311adbfd2","type":"obo:SEPIO_0004097","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"cggv:e6298385-e40d-4d57-bab0-bb3311adbfd2_variant_evidence_item"}],"strengthScore":0.1}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria"}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":8055,"specifiedBy":"GeneValidityCriteria10","strengthScore":15,"subject":{"id":"cggv:3459aed2-331c-45a4-929d-ba28f1424b06","type":"GeneValidityProposition","disease":"obo:MONDO_0014647","gene":"hgnc:1424","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","dc:description":"CAD was first reported in relation to autosomal recessive developmental and epileptic encephalopathy in 2015 (Ng et al., PMID 25678555). Thirteen variants (missense, nonsense, frameshift, splice site) that have been reported in 8 probands in 5 publications (PMIDs 25678555, 28007989, 32117025, 32820246, 29396846) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 pts) has been reached. Patients have a range of symptoms, including early-onset epilepsy, developmental delay, developmental regression, and anemia. The disease mechanism appears to be biallelic loss of function. Heterozygous carriers are reportedly unaffected. This gene-disease relationship is also supported by the biochemical function of CAD, which is involved in de novo synthesis of uridine 5-monophosphate (UMP), the precursor of pyrimidine nucleotides (PMID 34288185). In vitro assays support a defect in this pathway and supplementation of uridine has been shown to improve the clinical outcome of patients with variants in CAD (PMIDs 25678555, 32461667). Studies in zebrafish and Drosophila also support a role in pyrimidine biosynthesis (PMIDs 15937129, 5004701). In summary, there is definitive evidence supporting the relationship between CAD and autosomal recessive developmental and epileptic encephalopathy. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. ","dc:isVersionOf":{"id":"cggv:e4a828c0-e00b-4756-aec7-b83e529ec8e4"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}